Azacytidine With Valproic Acid Versus Ara-C in Acute Myeloid Leukemia (AML)/ Myelodysplastic Syndrome (MDS) Patients
Phase 2
Completed
- Conditions
- Acute Myelogenous LeukemiaMyelodysplastic SyndromeLeukemia
- Interventions
- First Posted Date
- 2006-09-29
- Last Posted Date
- 2012-08-07
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 11
- Registration Number
- NCT00382590
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
FCR Plus Sargramostim (GM-CSF) as Frontline Therapy for Symptomatic Chronic Lymphocytic Leukemia
Phase 2
Completed
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- First Posted Date
- 2006-09-27
- Last Posted Date
- 2016-01-14
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 60
- Registration Number
- NCT00381004
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
The Effects of Thalidomide on Symptom Clusters
- First Posted Date
- 2006-09-21
- Last Posted Date
- 2013-02-04
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 32
- Registration Number
- NCT00379353
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Heparin or M-EDTA in Preventing Catheter-Related Infections and Blockages in Patients at High Risk for a Catheter-Related Infection
- First Posted Date
- 2006-09-21
- Last Posted Date
- 2012-02-24
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT00378781
Therapy of Chronic Lymphocytic Leukemia With Dasatinib (BMS-354825)
- First Posted Date
- 2006-08-15
- Last Posted Date
- 2023-12-19
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 17
- Registration Number
- NCT00364286
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Revlimid in Patients With Acute Myelogenous Leukemia and Myelodysplastic Syndrome
Phase 2
Completed
- Conditions
- Acute Myelogenous LeukemiaMyelodysplastic Syndrome
- Interventions
- First Posted Date
- 2006-08-07
- Last Posted Date
- 2013-08-14
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 27
- Registration Number
- NCT00360672
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Pharmacokinetic Evaluation of Rasburicase in Patients With Leukemia and/or Lymphoma at High Risk of TLS
- First Posted Date
- 2006-08-04
- Last Posted Date
- 2012-08-01
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 18
- Registration Number
- NCT00360438
- Locations
- 🇺🇸
The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States
Prognostic Molecular and Environmental Factors in High-Risk Colon Cancer Patients
- Conditions
- Colon Cancer
- Interventions
- Behavioral: Questionnaire
- First Posted Date
- 2006-07-20
- Last Posted Date
- 2019-05-10
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 200
- Registration Number
- NCT00354705
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Imatinib in Combination With Dacarbazine and Capecitabine in Medullary Thyroid Carcinoma
Phase 1
Terminated
- Conditions
- Solid TumorThyroid Cancer
- Interventions
- First Posted Date
- 2006-07-20
- Last Posted Date
- 2014-12-17
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 21
- Registration Number
- NCT00354523
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Study of FOLFIRI Plus Bevacizumab in Colorectal Cancer Patients
Phase 2
Completed
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2006-07-20
- Last Posted Date
- 2011-10-21
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 49
- Registration Number
- NCT00354978
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Lyndon Baines Johnson General Hospital, Houston, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath